Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...
Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results